Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas and Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.…
What Is Novartis (SWX:NOVN) Gaining From Its PMR Approval And ADC Deal?
Active Biotech (STO: ACTI) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 5 employees.
The shares were at 3.360 SEK on 20 November 2026, down 45.7% over 52 weeks. Its 52-week range is 3.100 SEK to 9.430 SEK: the price is 64.4% below the high and 8.4% above the low.
Its market capitalisation is 88.57M SEK.
Active Biotech reports return on equity of -67.1% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 36.30M SEK. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.